MS patients may ditch IV drips for At-Home shots

NCT ID NCT04486716

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether people with relapsing multiple sclerosis can safely switch from an intravenous (IV) anti-CD20 antibody treatment to a self-injected drug called ofatumumab. 111 adults took part, and researchers tracked their brain scans and side effects for a year. The goal was to see if the switch kept the disease from flaring up.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ofatumumab (a drug given as a shot under the skin)
What this could lead to: If successful, this could show that switching to a convenient at-home injection is a safe and effective way to keep multiple sclerosis in check.
What could go wrong: This is a single-arm study with no comparison group, so results may not prove superiority over staying on IV therapy. It also only followed patients for 12 months, so long-term effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS

Contacts and locations

Show contact details

Locations

AMO Corporation

Tallahassee, Florida, 32312, United States
Alabama Neurology Associates PC

Birmingham, Alabama, 35209, United States
Beth Israel Deaconess Medical Cente

Boston, Massachusetts, 02215, United States
Caribbean Center for Clinical Research, Inc

Guaynabo, 00968, Puerto Rico
Central TX Neuro Consultants P A

Round Rock, Texas, 78681, United States
Cleveland Clinic Foundation

Las Vegas, Nevada, 89106, United States
Columbus Neuroscience

Westerville, Ohio, 43082, United States
Ctr for Neurology and Spine

Phoenix, Arizona, 85018, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Dragonfly Research LLC

Wellesley, Massachusetts, 02481, United States
Infinity Clinical Research LLC

Hollywood, Florida, 33024, United States
International Neurorehab Institute

Lutherville, Maryland, 21093, United States
Ms Ctr Of Northeastern Ny

Latham, New York, 12110, United States
Neuro Center

Pomona, California, 91767, United States
Neurology Center of New England PC

Foxborough, Massachusetts, 02035, United States
Parkland Health and Hospital Systems

Dallas, Texas, 75325, United States
Sibyl Wray MD Neurology PC

Knoxville, Tennessee, 37922, United States
Swedish Neuroscience Institute

Seattle, Washington, 98122, United States
UC Health Neuroscience Ctr

Aurora, Colorado, 80045, United States
University Of South Florida

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.